NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2021 and provided corporate highlights.
PMV Pharmaceuticals reported its Q2 2021 financial results, highlighting the continued enrollment in the Phase 1/2 trial of PC14586 and ending the quarter with $339.0 million in cash, cash equivalents, and marketable securities.
- Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586.
- Activated twelve clinical trial sites in the United States.
- Commenced construction of new corporate headquarters and state-of-the-art laboratories in Princeton, New Jersey.
- Ended the second quarter with $339.0 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
The company provided forward-looking statements regarding future plans and expectations for PC14586, its discovery platform, and its ability to fund its operating plan.
Tailwinds
- Expectations regarding the timing for patient enrollment.
- Success of its current clinical trial for PC14586.
- Future plans or expectations for the Company’s discovery platform.
- Estimates its existing cash and cash equivalents will be sufficient to fund its current operating plan.
- Focus on delivering precision therapeutics that improve the lives of patients living with cancer.
Headwinds
- The success, cost, and timing of the Company’s product candidate development activities and planned clinical trials.
- The Company’s ability to execute on its strategy and operate as an early clinical stage company.
- The potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results.
- The Company’s ability to fund operations.
- The impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro